56
Participants
Start Date
June 25, 2019
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Von Willebrand Factor-Containing Product
Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
Medical Centre Hungarian Defence Forces, Budapest
Debreceni Egyetem Klinikai Központ, Regionális Haemophilia és Thrombophilia Központ, Debrecen
University Clinical Center, Department of Internal Medicine, Hematology, Pécs
"UMHAT Sveta Marina EAD.", Varna
University Hospital Centre Zagreb, Zagreb
Children's Healthcare of Atlanta, Atlanta
"Community Institution of Lviv Oblast Council West-Ukrainian Specialized Children's Medical Center", Lviv
Morosovskaya Children Clinical Hospital, Moscow Health Department, Department of General Hematology with the Pathology of Hemostasis, Moscow
Federal State Budgetary Scientific Institution Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal, Kirov
Republican Research Center for Radiation Medicine and Human Ecology, Homyel
"Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia", Sofia
American University of Beirut Medical Center, Beirut
Nini Hospital, Tripoli
Hotel Dieu de France Hospital, Beirut
"State Institution National Children's Specialized Hospital OKHMATDYT of the Ministry of Health of Ukraine, Center of Hemostasis Pathology", Kyiv
Lead Sponsor
Octapharma
INDUSTRY